4.6 Article

Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization

期刊

ANNALS OF MEDICINE
卷 36, 期 3, 页码 232-240

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/07853890410031236

关键词

neuropeptide Y; retinopathy; Y2-receptor

资金

  1. NHLBI NIH HHS [HL67357] Funding Source: Medline
  2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067357] Funding Source: NIH RePORTER

向作者/读者索取更多资源

BACKGROUND: Neuropeptide Y is a sympathetic neurotransmitter, a potent endothelium-derived angiogenic factor and a vascular mitogen. We have studied the role of the functional leucine7 to proline7 polymorphism of the signal peptide region of preproneuropeptide Y (prepro-NPY) as a genetic susceptibility factor for diabetic retinopathy. In addition, we investigated the role of the NPY Y2-receptor as a putative mediator of angiogenic NPY signaling in the retina. METHODS: Frequencies of proline7 (Pro7) carriers in the prepro-NPY were determined in type 1 and type 2 diabetes patients having retinopathy, in type 2 diabetes patients without retinopathy and in healthy control subjects. The role of Y2-receptor in hyperoxemia-induced retinal neovascularization was investigated in Y2-receptor knockout mice (Y2(-/-)) and in rats administered Y2-receptor mRNA antisense oligonucleotide. RESULTS: The carriers having Pro? in the preproNPY are markedly over-represented among type 2 diabetes patients with retinopathy compared to type 2 diabetes patients without retinopathy and to the population control. Neonatal exposure to hyperoxia resulted in development of retinal neovascularization that was prevented in Y2(-/-)-mice, and significantly inhibited in rats treated with the Y2-receptor antisense oligonucleotide. CONCLUSIONS: NPY and Y2-receptor play important roles in diabetic retinopathy and retinal neovascularization and are thus potential new targets for drug molecules for treatment of retinopathy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据